Adempas and Triamcinolone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Adempas (riociguat) and Triamcinolone (triamcinolone). Common drug interactions include oxygen consumption increased among females and chills among males.

The phase IV clinical study analyzes what interactions people have when they take Adempas and Triamcinolone. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.

What is Triamcinolone?

Triamcinolone has active ingredients of triamcinolone. eHealthMe is studying from 25,577 Triamcinolone users. Check the latest studies of Triamcinolone.



On Jul, 07, 2026

23 people who take Adempas and Triamcinolone together, and have interactions are studied.

Adempas and Triamcinolone drug interactions.

What are the common drug interactions of Adempas and Triamcinolone, by gender? *:

female:

  1. Oxygen consumption increased
  2. Painful respiration
  3. Palpitations (feelings or sensations that your heart is pounding or racing)
  4. Peripheral swelling
  5. Pleurisy (inflammation of the pleurae, which causes pain when breathing)
  6. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
  7. Pulmonary oedema (fluid accumulation in the lungs)
  8. Purulence (containing pus)
  9. Respiratory distress (difficulty in breathing)
  10. Rhinitis allergic (inflammation of the nasal airways due to allergy)

male:

  1. Chills (felling of cold)
  2. Fatigue (feeling of tiredness)
  3. Syncope (loss of consciousness with an inability to maintain postural tone)
  4. Abdominal pain upper
  5. Asthenia (weakness)
  6. Autoimmune disorder (a condition in which the immune system attacks the body's normal substances and tissue)
  7. Death
  8. Diarrhoea
  9. Dizziness
  10. Dizziness exertional

What are the common drug interactions of Adempas and Triamcinolone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Anger
  2. Anxiety
  3. Depressed mood
  4. Diarrhoea
  5. Dizziness
  6. Dyspnoea (difficult or laboured respiration)
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Ear infection
  9. Flushing (the warm, red condition of human skin)
  10. Head injury

30-39:

n/a

40-49:

  1. Abdominal pain
  2. Arthralgia (joint pain)
  3. Chest pain
  4. Cough
  5. Dizziness
  6. Dizziness exertional
  7. Dyspnoea (difficult or laboured respiration)
  8. Fatigue (feeling of tiredness)
  9. Haemoglobin decreased
  10. Headache (pain in head)

50-59:

  1. Chest pain
  2. Chills (felling of cold)
  3. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  4. Conjunctival haemorrhage (bleeding underneath the conjunctiva)
  5. Cough
  6. Diarrhoea
  7. Dizziness
  8. Dysphagia (a condition in which swallowing is difficult or painful)
  9. Dyspnoea (difficult or laboured respiration)
  10. Dyspnoea exertional (breathlessness or shortness of breath)

60+:

  1. Joint swelling
  2. Pyrexia (fever)
  3. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
  4. Peripheral swelling
  5. Pulmonary mass
  6. Rib fracture
  7. Weight increased
  8. Accident
  9. Fall
  10. Respiratory disorder (respiratory disease)

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 17 people, 73.91%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 13.04%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 13.04%
  4. Infusion Site Pain: 3 people, 13.04%
  5. Pain: 2 people, 8.70%
  6. Infusion Site Erythema (reddening of the skin at infusion site): 2 people, 8.70%
  7. Infusion Site Discomfort: 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and Triamcinolone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Adempas and Triamcinolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Triamcinolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Adempas and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Triamcinolone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on riociguat and triamcinolone (the active ingredients of Adempas and Triamcinolone, respectively), and Adempas and Triamcinolone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: